C1 esterase inhibitor use in the management of lisinopril-induced angioedema: A case series.

IF 2.5

Journal of the American Pharmacists Association : JAPhA Pub Date : 2020-11-01 Epub Date: 2020-07-26 DOI:10.1016/j.japh.2020.06.025

Francisco Ibarra, Mallory Cruz

{"title":"C1 esterase inhibitor use in the management of lisinopril-induced angioedema: A case series.","authors":"Francisco Ibarra, Mallory Cruz","doi":"10.1016/j.japh.2020.06.025","DOIUrl":null,"url":null,"abstract":"Objective: Review 4 patients who presented with presumed lisinopril-induced angioedema and received C1 esterase inhibitor (C1-INH).Case summary: Four patients received C1-INH for presumed lisinopril-induced angioedema. In all cases, angioedema was attributed to lisinopril use after the patients' symptoms did not resolve after receiving other interventions. The patients received either 1500 units or 2000 units of C1-INH. All patients' symptoms resolved after receiving a single C1-INH dose, and all were discharged home within 48 hours of receiving C1-INH.Practice implications: On the basis of the available literature and our study, C1-INH may effectively treat angiotensin-converting enzyme inhibitor-induced angioedema (ACEi-AE). Owing to the low incidence of ACEi-AE and the high cost of C1-INH, physicians should consider limiting the use of C1-INH to patients who remain symptomatic after the initial interventions and are at risk of a compromised airway.","PeriodicalId":520694,"journal":{"name":"Journal of the American Pharmacists Association : JAPhA","volume":" ","pages":"e361-e364"},"PeriodicalIF":2.5000,"publicationDate":"2020-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.japh.2020.06.025","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the American Pharmacists Association : JAPhA","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.japh.2020.06.025","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/7/26 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 2

Abstract

Objective: Review 4 patients who presented with presumed lisinopril-induced angioedema and received C1 esterase inhibitor (C1-INH).

Case summary: Four patients received C1-INH for presumed lisinopril-induced angioedema. In all cases, angioedema was attributed to lisinopril use after the patients' symptoms did not resolve after receiving other interventions. The patients received either 1500 units or 2000 units of C1-INH. All patients' symptoms resolved after receiving a single C1-INH dose, and all were discharged home within 48 hours of receiving C1-INH.

Practice implications: On the basis of the available literature and our study, C1-INH may effectively treat angiotensin-converting enzyme inhibitor-induced angioedema (ACEi-AE). Owing to the low incidence of ACEi-AE and the high cost of C1-INH, physicians should consider limiting the use of C1-INH to patients who remain symptomatic after the initial interventions and are at risk of a compromised airway.

查看原文本刊更多论文

C1酯酶抑制剂在赖诺普利诱导血管性水肿治疗中的应用:一个病例系列。

目的:回顾4例假定赖诺普利诱导血管性水肿并接受C1酯酶抑制剂(C1- inh)治疗的患者。病例总结:4例患者因假定赖诺普利引起的血管性水肿接受C1-INH治疗。在所有病例中，在接受其他干预措施后症状未缓解后，血管性水肿归因于使用赖诺普利。患者接受1500单位或2000单位的C1-INH治疗。所有患者在接受单次C1-INH治疗后症状均缓解，并在接受C1-INH治疗后48小时内出院。实践意义:根据现有文献和我们的研究，C1-INH可有效治疗血管紧张素转换酶抑制剂诱导的血管性水肿(ACEi-AE)。由于ACEi-AE的低发病率和C1-INH的高成本，医生应考虑将C1-INH的使用限制在初始干预后仍有症状且有气道受损风险的患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of the American Pharmacists Association : JAPhA

自引率

0.00%

发文量